Valeria Gerthofer Alexander Scheiter Florian Lüke Felix Keil Kirsten Utpatel Laura-Maria-Giovanna Pöhmerer Johannes Seitz Christoph Niessen Atanas Ignatov Wolfgang Dietmaier Diego F Calvisi Matthias Evert Olaf Ortmann Stephan Seitz
10.1200/PO.21.00184
JCO Precis Oncol
2021 Sep 16;5:PO.21.00184.
CC BY-NC-ND
https://pubmed.ncbi.nlm.nih.gov/34568722/
Anaplastic Lymphoma Kinase / analysis Calmodulin-Binding Proteins / analysis Crizotinib / therapeutic use Membrane Proteins / analysis Mesothelioma, Malignant / drug therapy Nerve Tissue Proteins / analysis Organophosphorus Compounds / therapeutic use Peritoneum / abnormalities Pyrimidines / therapeutic use
Anaplastic Lymphoma Kinase / analysis Calmodulin-Binding Proteins / analysis Crizotinib / therapeutic use Membrane Proteins / analysis Mesothelioma, Malignant / drug therapy Nerve Tissue Proteins / analysis Organophosphorus Compounds / therapeutic use Peritoneum / abnormalities Pyrimidines / therapeutic use Case Reports Abdominal Pain / etiology Anaplastic Lymphoma Kinase / genetics Antineoplastic Agents / therapeutic use Calmodulin-Binding Proteins / genetics Female Humans Membrane Proteins / genetics Nerve Tissue Proteins / genetics Peritoneum / drug effects Peritoneum / physiopathology Young Adult Antineoplastic Agents Calmodulin-Binding Proteins Membrane Proteins Nerve Tissue Proteins Organophosphorus Compounds Pyrimidines STRN protein, human Crizotinib ALK protein, human Anaplastic Lymphoma Kinase brigatinib
PMC8462007
34568722
STRN-ALK Fusion in a Case of Malignant Peritoneal Mesothelioma: Mixed Response to Crizotinib, Mode of Resistance, and Brigatinib Sequential Therapy
2021